GI CONNECT
@giconnectInfo
Followers
2K
Following
506
Media
411
Statuses
1K
COR2ED brings you Independent Medical Education developed by GI CONNECT, international experts in GI oncology. https://t.co/CePZ1NKOt9
Joined July 2015
👴 Patient case: 61y male with #CRC progression following chemotherapy + monoclonal antibody treatment Which treatment decisions would you make for him, 2nd, 3rd line + beyond? Test your knowledge in this patient case video from Prof. @andrea_sart 📺 Later- line treatment
0
0
0
📢 Come and visit us in Berlin at #ESMO25! We'll be at Booth 4025 offering FREE profile headshots from our professional photographer, and showcasing our range of high-quality Independent #MedicalEducation programmes across multiple therapy areas. See you there! #IME
1
11
16
📣 Join the discussion! Experts will review the latest data on gastric & gastroesophageal cancer from #ESMO25 in a virtual Experts Knowledge Share What will new data mean for clinical practice? 19th November 17:00 -18:15 CET / 11:00 -12:15 EST Register now to save your place:
0
0
1
GI CONNECT podcast episode Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) @DrShubhamPant & Prof. @efratdotan discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of
0
14
66
📣 GI CONNECT podcast episode 📣 ➡️Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) @DrShubhamPant & Prof. @efratdotan discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of
0
0
2
mPDAC is notoriously aggressive with a poor prognosis. Most patients are diagnosed at an advanced stage and need chemotherapy as soon as possible. In this podcast, Profs. @DrShubhamPant & @efratdotan discuss how to select and optimise first- and second-line chemotherapeutic
0
2
5
New #NETs video! 📹 Expert perspectives on PRRT and emerging strategies in #neuroendocrine tumours Explore diagnostic strategies, pt selection based on clinical trials, safety profiles/AE management, future directions & more! w/ Dr @helops79 @ProfKHerrmann @OncBrothers 🤝
0
0
0
New! #CRC #MedEd programme 🎓 ‘Later-line treatment strategies in metastatic colorectal cancer’ ✅ It’s important to use all available therapeutics for pts w/ advanced #CRC But how can we determine who is suitable for rechallenge? 📺 Prof. @andrea_sart takes you through a
0
0
1
📢 Come and visit us in Berlin at #ESMO25! We'll be at Booth 4025 offering FREE profile headshots from our professional photographer & showcasing our range of high-quality Independent #MedicalEducation programmes across multiple therapy areas. See you there! #IME #MedTwitter
0
12
14
Frontline Tx regimens in mPDAC should be individualised based on: 🔸performance status 🔸comorbidities 🔸risk of neuropathy 👉 FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles What else do HCPs need to know about
0
0
1
Later-line strategies in metastatic #colorectalcancer: rechallenge or switch? 📺 Patient case video w/ Prof. @andrea_sart 🤝 Endorsed by @WarOnCancer @dice_europe Supported by an Independent Educational Grant from Bayer #CRC #CRCSM #MedEd #OncTwitter
0
0
1
Systemic chemotherapy is standard Tx for metastatic PDAC, but molecularly targeted Txs & IO may have a role for specific pts >> Explore 2nd line treatment options in an animated video from Prof. @efratdotan ‘Chemotherapy strategies for mPDAC’ Watch the video in this post 📺
3
7
52
Systemic chemotherapy is standard Tx for metastatic PDAC, but molecularly targeted Txs & IO may have a role for specific pts >> Explore this topic in an animated video from Prof. Eileen O’Reilly ‘Chemotherapy strategies for MPDAC’ Watch the video in this post 📺 Endorsed by
3
6
55
Metastatic pancreatic ductal adenocarcinoma (mPDAC) ➡️notoriously aggressive ➡️poor prognosis ➡️often diagnosed late ➡️surgery is usually not an option This is why chemotherapy strategies really matter Podcast discussion from Prof. @DrShubhamPant & Prof. @efratdotan Watch the
1
3
8
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced, incurable stage and carries a poor prognosis In the second video in this 2-part series, Prof Efrat Dotan explores second-line chemo options and treatment sequencing, with insights from CONKO-003,
0
1
6
Clinicians should consider all available therapeutic options when managing advanced metastatic colorectal cancer (mCRC) Assess the treatment options for a 61-year-old man with advanced mCRC following progression on chemotherapy and a monoclonal antibody. Make your treatment
0
0
3
After progression on 1st-line immunotherapy (IO), multiple treatment strategies are available for patients with advanced hepatocellular carcinoma (HCC). Experts Assoc. Prof. Lorenza Rimassa and Dr Amit Singal focus on options for patients who are ineligible for IO or those with
0
0
2
Later-line treatment strategies in metastatic colorectal cancer: Rechallenge vs switching What do HCPs need to know about later-line Tx options in metastatic colorectal cancer? 📺 Video in this post >> w/ Prof. @andrea_sart Clinical takeaways include: - Advanced CRC
9
72
557
Systemic chemo is the standard 1st-line treatment for metastatic PDAC, but targeted therapies and immunotherapies may benefit select patients In video 1 of 2, Prof Eileen O’Reilly reviews key clinical trials including PRODIGE, MPACT, NAPOLI-3, and POLO. Check out the video on
0
1
1